Raj Singh1, John Austin Vargo2, Shiyu Song3. 1. Department of Radiation Oncology, Virginia Commonwealth University Health System, Richmond, VA, 23219, USA. raj.singh@vcuhealth.org. 2. Department of Radiation Oncology, University of Pittsburgh Hillman Cancer Center, Pittsburgh, PA, USA. 3. Department of Radiation Oncology, Virginia Commonwealth University Health System, Richmond, VA, 23219, USA.
Abstract
OBJECTIVES: Current trials for HPV-associated oropharyngeal SCCs (OP-SCCs) are evaluating treatment de-escalation including use of concurrent immunotherapy with radiation therapy (I-RT). Given limited prospective data following I-RT, we aimed to examine this question utilizing the National Cancer Data Base (NCDB). METHODS: The NCDB was queried for patients with HPV-associated OP-SCCs eligible for current de-escalation studies with AJCC 7th edition T1-T2/N1-N2b and T3/N0-N2b disease. Patients were stratified into I-RT, concurrent chemoradiation (C-RT), and radiation therapy alone (RT) arms. Kaplan-Meier analysis was utilized to compare overall survival (OS) between treatment arms followed by a Cox multivariate (MVA) proportional hazards model controlling for tumor and patient characteristics and propensity-score analyses with inverse probability treatment weighting (IPTW). RESULTS: We identified 4768 patients; 313 received I-RT, 3660 patients received C-RT, and 795 received RT. Median age was 62 years (range 27-90) with a median Charlson-Deyo co-morbidity score of 0 (range: 0-3). The vast majority were cN1-N2a (88.8%) and 26.5% were cT3. On MVA, inferior 3-year and 8-year OS was noted following I-RT (81.6% and 70.5%) vs. C-RT (90.6% and 79.4%) (HR = 1.69 (95% CI: 1.29-2.21); p < 0.0001) with no significant difference vs. RT (88.1% and 75.8%) (HR = 1.07; p = 0.80). This was also maintained on IPTW-analysis (HR = 1.62 (95% CI: 1.23-2.15); p = 0.001). CONCLUSIONS: I-RT was associated with significantly poorer OS vs. C-RT with no benefit compared to RT for HPV-associated OP-SCCs. I-RT is not recommended outside of currently accruing clinical trials.
OBJECTIVES: Current trials for HPV-associated oropharyngeal SCCs (OP-SCCs) are evaluating treatment de-escalation including use of concurrent immunotherapy with radiation therapy (I-RT). Given limited prospective data following I-RT, we aimed to examine this question utilizing the National Cancer Data Base (NCDB). METHODS: The NCDB was queried for patients with HPV-associated OP-SCCs eligible for current de-escalation studies with AJCC 7th edition T1-T2/N1-N2b and T3/N0-N2b disease. Patients were stratified into I-RT, concurrent chemoradiation (C-RT), and radiation therapy alone (RT) arms. Kaplan-Meier analysis was utilized to compare overall survival (OS) between treatment arms followed by a Cox multivariate (MVA) proportional hazards model controlling for tumor and patient characteristics and propensity-score analyses with inverse probability treatment weighting (IPTW). RESULTS: We identified 4768 patients; 313 received I-RT, 3660 patients received C-RT, and 795 received RT. Median age was 62 years (range 27-90) with a median Charlson-Deyo co-morbidity score of 0 (range: 0-3). The vast majority were cN1-N2a (88.8%) and 26.5% were cT3. On MVA, inferior 3-year and 8-year OS was noted following I-RT (81.6% and 70.5%) vs. C-RT (90.6% and 79.4%) (HR = 1.69 (95% CI: 1.29-2.21); p < 0.0001) with no significant difference vs. RT (88.1% and 75.8%) (HR = 1.07; p = 0.80). This was also maintained on IPTW-analysis (HR = 1.62 (95% CI: 1.23-2.15); p = 0.001). CONCLUSIONS: I-RT was associated with significantly poorer OS vs. C-RT with no benefit compared to RT for HPV-associated OP-SCCs. I-RT is not recommended outside of currently accruing clinical trials.
Authors: K Kian Ang; Jonathan Harris; Richard Wheeler; Randal Weber; David I Rosenthal; Phuc Felix Nguyen-Tân; William H Westra; Christine H Chung; Richard C Jordan; Charles Lu; Harold Kim; Rita Axelrod; C Craig Silverman; Kevin P Redmond; Maura L Gillison Journal: N Engl J Med Date: 2010-06-07 Impact factor: 91.245
Authors: Liufu Deng; Hua Liang; Byron Burnette; Michael Beckett; Thomas Darga; Ralph R Weichselbaum; Yang-Xin Fu Journal: J Clin Invest Date: 2014-01-02 Impact factor: 14.808
Authors: Shanthi Marur; Shuli Li; Anthony J Cmelak; Maura L Gillison; Weiqiang J Zhao; Robert L Ferris; William H Westra; Jill Gilbert; Julie E Bauman; Lynne I Wagner; David R Trevarthen; Jahagirdar Balkrishna; Barbara A Murphy; Nishant Agrawal; A Dimitrios Colevas; Christine H Chung; Barbara Burtness Journal: J Clin Oncol Date: 2016-12-28 Impact factor: 44.544
Authors: Jared Weiss; Siddharth Sheth; Allision M Deal; Juneko E Grilley Olson; Samip Patel; Trevor G Hackman; Jeffrey M Blumberg; Thomas J Galloway; Shetal Patel; Adam M Zanation; Colette J Shen; D Neil Hayes; Christopher Hilliard; Ranee Mehra; Karen P McKinnon; Hsing-Hui Wang; Mark Christian Weissler; Jessica R Bauman; Bhishamjit S Chera; Benjamin G Vincent Journal: Clin Cancer Res Date: 2020-05-05 Impact factor: 12.531
Authors: Nadeem Riaz; Eric Sherman; Xin Pei; Heiko Schöder; Milan Grkovski; Ramesh Paudyal; Nora Katabi; Pier Selenica; Takafumi N Yamaguchi; Daniel Ma; Simon K Lee; Rachna Shah; Rahul Kumar; Fengshen Kuo; Abhirami Ratnakumar; Nathan Aleynick; David Brown; Zhigang Zhang; Vaios Hatzoglou; Lydia Y Liu; Adriana Salcedo; Chiaojung J Tsai; Sean McBride; Luc G T Morris; Jay Boyle; Bhuvanesh Singh; Daniel S Higginson; Rama R Damerla; Arnaud da Cruz Paula; Katharine Price; Eric J Moore; Joaquin J Garcia; Robert Foote; Alan Ho; Richard J Wong; Timothy A Chan; Simon N Powell; Paul C Boutros; John L Humm; Amita Shukla-Dave; David Pfister; Jorge S Reis-Filho; Nancy Lee Journal: J Natl Cancer Inst Date: 2021-06-01 Impact factor: 13.506
Authors: Nancy Y Lee; Robert L Ferris; Amanda Psyrri; Robert I Haddad; Makoto Tahara; Jean Bourhis; Kevin Harrington; Peter Mu-Hsin Chang; Jin-Ching Lin; Mohammad Abdul Razaq; Maria Margarida Teixeira; József Lövey; Jerome Chamois; Antonio Rueda; Chaosu Hu; Lara A Dunn; Mikhail Vladimirovich Dvorkin; Steven De Beukelaer; Dmitri Pavlov; Holger Thurm; Ezra Cohen Journal: Lancet Oncol Date: 2021-04 Impact factor: 54.433